Moderate

Non-tuberculous mycobacterial (NTM) lung disease (MAC, M. abscessus, etc.)

ntm-lung-disease · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic pulmonary infection by environmental mycobacteria (commonly Mycobacterium avium complex, M. kansasii, M. abscessus) - distinct from tuberculosis. Diagnosis requires combined clinical, radiological and microbiological criteria (repeated positive cultures). Treatment is prolonged multidrug therapy; not every isolate needs treating.

Red flags

  • Cavitary or rapidly progressive disease
  • M. abscessus or macrolide-resistant isolate (poor prognosis, specialist care)
  • Massive haemoptysis
  • Significant weight loss / respiratory failure
  • Macrolide monotherapy exposure (risk of resistance - avoid)

Assessment

Differential diagnosis

  • Pulmonary tuberculosis
  • Bronchiectasis (often coexists / predisposes)
  • COPD
  • Chronic aspiration
  • Fungal infection (aspergillosis)
  • Lung cancer
  • Hypersensitivity pneumonitis

Investigations

  • Sputum (or bronchoscopic) AFB smear + mycobacterial culture WITH species identification - need >=2 positive sputum cultures (or 1 positive BAL/biopsy) plus clinical + radiological criteria (ATS/IDSA)
  • Drug-susceptibility testing (esp. macrolide and amikacin for MAC; macrolide + inducible resistance for M. abscessus)
  • HRCT thorax (nodular-bronchiectatic or fibrocavitary patterns)
  • Exclude/treat coexisting TB; HIV test; assess immune status
  • Baseline before therapy: LFTs, renal function, FBC, visual acuity + colour vision (ethambutol), audiometry + ECG/QTc (macrolide/aminoglycoside), weight
  • Assess for predisposing bronchiectasis/structural lung disease

Management

  • Distinguish colonisation from true disease using full ATS/IDSA criteria - do NOT treat a single isolate without clinical/radiological disease
  • Identify species and obtain susceptibilities - this dictates the regimen and prognosis
  • Decide to treat based on symptoms, radiology, species virulence, and patient goals (prolonged, toxic therapy)
  • MAC pulmonary disease: macrolide-based three-drug regimen (azithromycin + rifampicin + ethambutol); add/consider amikacin (IV or inhaled) in cavitary/severe or refractory disease
  • M. kansasii: rifampicin + ethambutol + isoniazid or a macrolide
  • M. abscessus: refer to specialist - multidrug (macrolide if susceptible + IV amikacin + tigecycline/imipenem etc.); often difficult, low cure
  • Continue treatment until culture-negative for ~12 months (long courses, typically 15-18+ months)
  • Airway clearance for bronchiectasis; optimise nutrition; monitor drug toxicity (eyes, ears, liver, renal, QTc)
  • Manage in a specialist respiratory/infection service

Drugs & doses

MAC: azithromycin 250-500 mg PO once daily (or thrice weekly in nodular-bronchiectatic disease) [verify local dose]
MAC: rifampicin 10 mg/kg PO once daily (max 600 mg)
MAC: ethambutol 15 mg/kg PO once daily (monitor visual acuity/colour vision)
Amikacin IV or inhaled (liposomal amikacin for refractory MAC) - specialist, with audiometry/renal monitoring [verify dose]
M. kansasii: rifampicin + ethambutol + (isoniazid or macrolide) [verify regimen]
M. abscessus (specialist): macrolide (if no inducible resistance) + IV amikacin + imipenem/tigecycline/cefoxitin combination [verify regimen]

Disposition

Specialist respiratory/infectious-disease management; mostly outpatient with monitored long-term therapy. Admit for haemoptysis, respiratory failure, or IV-therapy initiation. Not all isolates require treatment.

Complications & pitfalls

  • Progressive lung destruction, bronchiectasis, respiratory failure
  • Macrolide resistance (worsens outcome markedly)
  • Drug toxicity: ocular (ethambutol), ototoxicity/nephrotoxicity (aminoglycosides), hepatotoxicity, QT prolongation
  • Haemoptysis
  • Treatment failure / relapse

Exam pearls

  • A single positive NTM culture does NOT equal disease - apply full ATS/IDSA/ERS/BTS criteria (clinical + radiological + >=2 positive cultures) before committing to long toxic therapy (ATS/IDSA 2020).
  • Never use a macrolide as monotherapy for NTM - resistance develops and ruins the key drug.
  • MAC is the commonest; treat until culture-negative for ~12 months (overall 15-18+ months).
  • M. abscessus is often multidrug-resistant and should be managed in a specialist centre; macrolide activity depends on inducible erm gene resistance.
  • Always exclude TB and look for underlying bronchiectasis.
  • Monitor ethambutol vision, aminoglycoside hearing/renal function, and QTc throughout.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.